The FDA on October 27, 2023, approved LOQTORZ® (Toripalimab-tpzi) with Cisplatin and Gemcitabine for the first-line treatment of adults with metastatic or recurrent, locally advanced Nasopharyngeal carcinoma. The FDA also approved LOQTORZ® as a single agent for adults with recurrent unresectable or metastatic Nasopharyngeal carcinoma with disease progression on or after a platinum-containing chemotherapy. LOQTORZ® is a product of Coherus BioSciences, Inc.
Top Ad
Advertisement